Puma Biotechnology
PBYI
178 hedge funds and large institutions have $2.42B invested in Puma Biotechnology in 2018 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 83 increasing their positions, 51 reducing their positions, and 47 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 51
2.12% less ownership
Funds ownership: 96.46% → 94.33% (-2.1%)
12% less funds holding
Funds holding: 203 → 178 (-25)
22% less call options, than puts
Call options by funds: $29.6M | Put options by funds: $38.1M
33% less capital invested
Capital invested by funds: $3.59B → $2.42B (-$1.17B)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
47% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$76.4M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$61.8M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$37.4M |
| 4 |
Jennison Associates
New York
|
+$36.4M |
| 5 |
O
OrbiMed
New York
|
+$34.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$148M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$142M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$61.6M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$44M |
| 5 |
CCS
Crosspoint Capital Strategies
Orinda,
California
|
-$34.9M |
PBYI Hedge Fund Activity: Q1 2018 in Review
178 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q1 2018, worth a combined $2.42B — down 33% from $3.59B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of PBYI and 25 opened new positions — a net loss of 22 holders — while 51 trimmed existing stakes and 83 added.
The largest buyer was Point72 Asset Management, adding an estimated $76.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $148M.
- 178 institutional investors held Puma Biotechnology (PBYI) as of Q1 2018, down from 203 in Q4 2017.
- Funds reported $2.42B of Puma Biotechnology stock for Q1 2018, down 33% quarter-over-quarter.
- 25 funds opened new Puma Biotechnology positions in Q1 2018 and 47 closed out, a net change of -22 holders.
- The largest Puma Biotechnology buyer in Q1 2018 was Point72 Asset Management, an estimated $76.4M added.
- The largest Puma Biotechnology seller in Q1 2018 was T. Rowe Price Associates, an estimated $148M sold.
Based on aggregated 13F filings for Q1 2018.